TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 2971977
Drug: Metered dose
Normalized name: Metered Dose Inhaler
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metered dose aerosol of 200 micrograms fenoterol plus 80 micrograms ipratropium bromide ('Duovent')
Study: 2971977
Drug: Dry powder
Normalized name: Dry Powder Inhaler
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dry powder preparation for inhalation ('Inhalets') of 200 micrograms fenoterol plus 80 micrograms ipratropium bromide ('Duovent')
Study: 28347865
Drug: Mechanical curettage
Normalized name: PIPERONYL BUTOXIDE TECHNICAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mechanical curettage with adjunct antimicrobial photodynamic therapy (aPDT)
Study: 20848527
Drug: Boswelan (3×2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Boswelan (3×2 capsules/day; 400 mg each)
Study: 19918682
Drug: Healer cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Healer cream applied 3 times daily
Study: 19918682
Drug: Nitroglycerine 0.25%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitroglycerine 0.25% cream applied 3 times daily
Study: 19918682
Drug: Lidocaine 2%
Normalized name: LIDOCAINE 2% GEL,TOP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine 2% cream applied 3 times daily
Study: 9580234
Drug: Diet +
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diet + 750 mg UDA + fiber placebo
Study: 9580234
Drug: Diet +
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diet + 15 g Pp + UDA placebo
Study: 3759281
Drug: L-carnitine, 2
Normalized name: L-Carnitine, 250 mg oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-carnitine, 2 g twice daily for 15 days
Study: 24288121
Drug: Topotecan (0.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topotecan (0.75 mg/m²) on days 1, 2, and 3, etoposide (70 mg/m²) and cisplatin (20 mg/m²) on days 8, 9, and 10 (Arm A)
Study: 24288121
Drug: Irinotecan (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irinotecan (50 mg/m²) and cisplatin (20 mg/m²) on days 1 and 8 followed by etoposide (85 mg/m² PO bid) on days 3 and 10 (Arm B)
Study: 19095597
Drug: Spironolactone 25
Normalized name: spironolactone 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spironolactone 25 mg once daily for 4 weeks
Study: 9797112
Drug: Liposomal lecithin
Normalized name: Lecithin
DrugBank: Lecithin (DB15834)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liposomal lecithin (1 mg/mL for 2 hours)
Study: 2569381
Drug: Ceftriaxone 4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftriaxone 4 x 1 g i.m. every 2 days
Study: 2569381
Drug: Penicillin G
Normalized name: penicillin G
DrugBank: Benzylpenicillin (DB01053)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Penicillin G 1 million IU i.m. daily for 15 days
Study: 28854534
Drug: Dexamethasone 4
Normalized name: dexamethasone 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone 4 mg i.v. after induction of anaesthesia
Study: 26267418
Drug: Antidepressants (ADs)
Normalized name: Stahist AD
DrugBank: Chlorcyclizine (DB08936)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Antidepressants (ADs) plus mood stabilizers continued for up to 3 years after achieving euthymia for 2 months
Study: 26267418
Drug: Antidepressants (ADs)
Normalized name: Stahist AD
DrugBank: Chlorcyclizine (DB08936)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Antidepressants (ADs) continued
Study: 26267418
Drug: Antidepressants (ADs)
Normalized name: Stahist AD
DrugBank: Chlorcyclizine (DB08936)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Antidepressants (ADs) discontinued
Study: 23792189
Drug: Patient Education
Normalized name: DIABETES PATIENT EDUCATION PACK
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient Education plus Manual Therapy (PE + MT)
Study: 22089463
Drug: IV golimumab
Normalized name: Golimumab
DrugBank: Golimumab (DB06674)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: IV golimumab 2‐4 mg/kg (± MTX) every 12 weeks
Study: 22089463
Drug: golimumab 50
Normalized name: GOLIMUMAB 50MG/0.5ML INJ SYRINGE
Approvals — FDA: no, EMA: no, PMDA: no
Description: golimumab 50 mg SC (± MTX) every 4 weeks
Study: 22089463
Drug: IV golimumab
Normalized name: Golimumab
DrugBank: Golimumab (DB06674)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: IV golimumab (2‐4 mg/kg)
Study: 10392323
Drug: Avitriptan (12.7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Avitriptan (12.7 mg)
Study: 10392323
Drug: Avitriptan (25.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Avitriptan (25.3 mg)
Study: 10392323
Drug: Avitriptan (38.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Avitriptan (38.0 mg)
Study: 9133311
Drug: Diltiazem (0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diltiazem (0.3 mg/Kg bolus, followed by 0.0028 mg/Kg/min infusion if needed)
Study: 9133311
Drug: Verapamil (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verapamil (75 micrograms/Kg bolus, with a second dose if needed)
Study: 9133311
Drug: Sokolow protocol
Normalized name: Olay Professional Acne Protocol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sokolow protocol (i.v. digital plus oral quinidine 400 to 1,200 mg)
Study: 3658286
Drug: Doxycycline 400
Normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Doxycycline 400 mg
Study: 3346865
Drug: Metronidazole 1500
Normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Metronidazole 1500 mg
Study: 19018865
Drug: Induction therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction therapy including new drugs
Study: 19018865
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of an alkylating drug with a novel agent
Study: 12215058
Drug: Fluoxetine and
Normalized name: fluoxetine and psycholeptics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine and sertraline
Study: 12943944
Drug: Serotonergic antidepressants
Normalized name: ANTIDEPRESSANTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serotonergic antidepressants
Study: 28109543
Drug: Everolimus (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Everolimus (1.5 mg or 3 mg) with reduced cyclosporine
Study: 22795453
Drug: Extended-release mixed
Normalized name: Amphetamine Mixed Salts Extended-Release Capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended-release mixed amphetamine salts (MAS-ER) and topiramate
Study: 16218799
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (Fenofibrate + Pravastatin)
Study: 12359197
Drug: Daily aspiration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily aspiration of seroma
Study: 10416042
Drug: Coenzyme Q10
Normalized name: Coenzyme Q10
DrugBank: Ubidecarenone (DB09270)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Coenzyme Q10 100 mg twice daily
Study: 7559695
Drug: Enoxaparin (administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoxaparin (administered at 12 hours preoperatively and 12 and 36 hours postoperatively)
Study: 2795592
Drug: Tyramine infusion
Normalized name: tyramine
DrugBank: Tyramine (DB08841)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tyramine infusion (TI)
Study: 25845222
Drug: Acupoint injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupoint injection of kakkonein (2 mL) into bilateral Fengchi (GB 20), once every other day for 8 weeks
Study: 25845222
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of compound levodopa (125 mg, twice a day) for 8 weeks
Study: 23975654
Drug: Vortioxetine co-administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vortioxetine co-administered with bupropion
Study: 23975654
Drug: Vortioxetine co-administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vortioxetine co-administered with fluconazole
Study: 23975654
Drug: Vortioxetine co-administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vortioxetine co-administered with ketoconazole
Study: 23975654
Drug: Vortioxetine co-administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vortioxetine co-administered with rifampicin
Study: 23975654
Drug: Vortioxetine co-administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vortioxetine co-administered with ethinyl estradiol/levonorgestrel
Study: 23975654
Drug: Vortioxetine co-administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vortioxetine co-administered with 5'-hydroxyomeprazole
Study: 17918294
Drug: Cisplatin 20
Normalized name: CISPLATIN 200MG/VIL (PF) INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisplatin 20 mg/m(2), days 1‐5, every 21 days (arm A, n=171)
Study: 17918294
Drug: Cisplatin 40
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin 40 mg/m(2)/weekly (arm B, n=164)
Study: 9294777
Drug: Subcutaneous administration
Normalized name: subcutaneous administration set
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous administration of bovine TSH, 10 units daily for 3 days
Study: 9294777
Drug: Daily oral
Normalized name: GEMTESA 75 MG Once-Daily Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily oral administration of L‐triiodothyronine 75 micrograms for 7 days
Study: 7870742
Drug: New generation
Approvals — FDA: no, EMA: no, PMDA: no
Description: New generation antidepressants (maprotiline, mianserin, viloxazine, trazodone, nomifensine, fluvoxamine, fluoxetine)
Study: 3346364
Drug: Sulpiride (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulpiride (100 mg, three times daily for 4 days, then 50 mg, three times daily for 90 days)
Study: 25023791
Drug: Intramyocardial bone
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramyocardial bone marrow cell (BMC) injection (97 ± 13 × 10(6) BMCs)
Study: 22680341
Drug: Namisol® (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Namisol® (5 mg THC) - Sublingual administration
Study: 22680341
Drug: Namisol® (6.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Namisol® (6.5 mg and 8.0 mg THC) - Oral administration
Study: 19763743
Drug: Darbepoetin alfa
Normalized name: Darbepoetin Alfa
DrugBank: Darbepoetin alfa (DB00012)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Darbepoetin alfa (DPO) targeting hemoglobin (Hb) of 12-13 g/dl
Study: 19763743
Drug: Correction of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Correction of anemia to 11 g/dl or more
Study: 11952885
Drug: Simvastatin (S)
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Simvastatin (S) 40 mg for 6 weeks, S 80 mg for 6 weeks, S 80 mg for 24 weeks
Study: 11952885
Drug: Atorvastatin (A)
DrugBank: Atorvastatin (DB01076)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atorvastatin (A) 20 mg for 6 weeks, A 40 mg for 6 weeks, A 80 mg for 24 weeks
Study: 11952885
Drug: Atorvastatin (A)
DrugBank: Atorvastatin (DB01076)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atorvastatin (A) 80 mg
Study: 11952885
Drug: Simvastatin (S)
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Simvastatin (S) 80 mg
Study: 7617812
Drug: Lithium-TCA treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lithium-TCA treatment
Study: 7617812
Drug: TCA-placebo treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: TCA-placebo treatment
Study: 2095133
Drug: Ibuprofen sugar-coated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen sugar-coated tablets (Dolo-Dolgit) 600 mg
Study: 2095133
Drug: Ibuprofen film-coated
Normalized name: ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ibuprofen film-coated tablets 600 mg (reference preparation)
Study: 31697573
Drug: NNS treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: NNS treatment (aspartame and sucralose)
Study: 28157599
Drug: One Session
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: One Session Treatment for specific phobias
Study: 24517053
Drug: Huzhang Tongfeng
Approvals — FDA: no, EMA: no, PMDA: no
Description: Huzhang Tongfeng Granule + Jinhuang Ointment (acute phase); Yinlian Tongfeng Granule (remission phase)
Study: 24517053
Drug: Diclofenac Sodium
Normalized name: Diclofenac Sodium
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Diclofenac Sodium Sustained Release Capsule + Jinhuang Ointment (acute phase); Benzbromarone (remission phase)
Study: 19505198
Drug: Zolpidem tartrate
Normalized name: Zolpidem Tartrate
DrugBank: Zolpidem (DB00425)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Zolpidem tartrate extended-release taken in combination with escitalopram
Study: 16918596
Drug: Topical hyaluronic
Normalized name: hyaluronate Topical Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical hyaluronic acid (HA) 0.2%
Study: 3296734
Drug: Oral metoclopramide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral metoclopramide (2 mg/kg/dose)
Study: 3296734
Drug: Intravenous metoclopramide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous metoclopramide (2 mg/kg/dose)
Study: 3296734
Drug: Prochlorperazine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prochlorperazine (10 mg/dose)
Study: 3296734
Drug: Metoclopramide (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoclopramide (oral and intravenous)
Study: 3296734
Drug: High-dose oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose oral and intravenous metoclopramide
Study: 27935580
Drug: Lenalidomide maintenance
Normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Lenalidomide maintenance treatment
Study: 27935580
Drug: Lenalidomide maintenance
Normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Lenalidomide maintenance treatment in patients aged >74 years
Study: 24726095
Drug: Raltegravir 800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Raltegravir 800 mg twice daily
Study: 24726095
Drug: Efavirenz 600
Normalized name: efavirenz 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Efavirenz 600 mg once daily plus tenofovir and lamivudine
Study: 10780154
Drug: Client-centered group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Client-centered group psychotherapy (twice a week, approximately 100 sessions)
Study: 10780154
Drug: Clinical standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clinical standard treatment (control group)
Study: 1306004
Drug: Heparin-glucuronylglucosaminoglycane combination
Normalized name: heparin, combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin-glucuronylglucosaminoglycane combination
Study: 29380190
Drug: Automated closed-loop
Approvals — FDA: no, EMA: no, PMDA: no
Description: Automated closed-loop goal-directed fluid therapy
Study: 29380190
Drug: Manual fluid
Normalized name: amniotic fluid (bovine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manual fluid administration (control)
Study: 27399350
Drug: Nω‐hydroxy‐nor‐L‐arginine (arginase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nω‐hydroxy‐nor‐L‐arginine (arginase inhibitor)
Study: 20397499
Drug: Groups E,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Groups E, F, G, and H (same post-and-core materials as Groups A-D without TSC)
Study: 18234424
Drug: G‐CSF (Filgrastim)
Approvals — FDA: no, EMA: no, PMDA: no
Description: G‐CSF (Filgrastim) 5 mcg/kg/day
Study: 18234424
Drug: G‐CSF (Filgrastim)
Approvals — FDA: no, EMA: no, PMDA: no
Description: G‐CSF (Filgrastim) 10 mcg/kg/day
Study: 18234424
Drug: Dose-intensified AC
Normalized name: Metered Dose Inhaler
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose-intensified AC followed by T
Study: 11223696
Drug: alpha(1)‐Adrenoceptor antagonists
Approvals — FDA: no, EMA: no, PMDA: no
Description: alpha(1)‐Adrenoceptor antagonists such as tamsulosin
Study: 11223696
Drug: Early treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early treatment with alpha-blockers
Study: 11223696
Drug: Chronic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chronic treatment with alpha-blockers
Study: 9137507
Drug: D‐galactose (1.9
Approvals — FDA: no, EMA: no, PMDA: no
Description: D‐galactose (1.9 g/kg BW per day)
Study: 9137476
Drug: D‐glucose‐containing electrolyte
Approvals — FDA: no, EMA: no, PMDA: no
Description: D‐glucose‐containing electrolyte infusions
Study: 31888699
Drug: Transcranial direct
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transcranial direct current stimulation (tDCS) administered to the motor cortex (M1) or dorso lateral prefrontal cortex (DLPFC) for 10 sessions over 4 weeks at 2 mA for 20 minutes.
Study: 31888699
Drug: Sham group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham group receiving no active tDCS treatment.
Study: 28844214
Drug: Chamomile ointment
Normalized name: Chamomile
DrugBank: Chamomile (DB14357)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chamomile ointment
Study: 23429642
Drug: Omeprazole 40
Normalized name: omeprazole 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 40 mg once daily for 5 days
Study: 23429642
Drug: Boceprevir 800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Boceprevir 800 mg three times daily for 5 days
Study: 23429642
Drug: Omeprazole 40
Normalized name: omeprazole 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 40 mg once daily + Boceprevir 800 mg three times daily for 5 days
Study: 16729287
Drug: 8 mg
Normalized name: alloin 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 mg MRA/kg body weight
Study: 15616416
Drug: Folic acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folic acid (5 mg) for 4 weeks
Study: 11207873
Drug: Selective estrogen
Normalized name: Selective estrogen receptor modulator
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selective estrogen receptor modulators
Study: 15064089
Drug: Androgen replacement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Androgen replacement therapy
Study: 9218932
Drug: Coca-Cola (325
Approvals — FDA: no, EMA: no, PMDA: no
Description: Coca-Cola (325 ml) with 100 mg itraconazole
Study: 9218932
Drug: Water (325
Approvals — FDA: no, EMA: no, PMDA: no
Description: Water (325 ml) with 100 mg itraconazole
Study: 3478276
Drug: Intra-cervical 15-Me
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-cervical 15-Me PGF2 alpha gel
Study: 6586395
Drug: Intracervical PGE2
Normalized name: PGE2
DrugBank: Dinoprostone (DB00917)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intracervical PGE2 gel
Study: 3478276
Drug: Intra-cervical gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-cervical gel alone (placebo)
Study: 16989163
Drug: Immunotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunotherapy with Hymenoptera venom
Study: 4616806
Drug: Chlormethiazole (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlormethiazole (500 mg in 10 ml dose)
Study: 4616806
Drug: Nitrazepam (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitrazepam (10 mg single dose)
Study: 4616806
Drug: Overall assessment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall assessment of treatment
Study: 31419313
Drug: Standard treatment:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment: 18 months of teriparatide followed by 18 months of denosumab
Study: 31419313
Drug: Cyclic treatment:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclic treatment: three separate 12-month cycles of 6 months of teriparatide followed by 6 months of denosumab
Study: 31419313
Drug: Cyclic treatment
Normalized name: cyclic AMP
DrugBank: Cyclic adenosine monophosphate (DB02527)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclic treatment
Study: 30583667
Drug: Consultation based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Consultation based on Health Belief Model (4 weekly sessions)
Study: 26700457
Drug: saline (0.9
Approvals — FDA: no, EMA: no, PMDA: no
Description: saline (0.9 mL)
Study: 26700457
Drug: capsaicin (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: capsaicin (3 mg in 0.2 mL saline with 7% Tween 80)
Study: 26700457
Drug: morphine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: morphine (10 mg kg(‐1))
Study: 26700457
Drug: butorphanol (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: butorphanol (10 mg kg(‐1))
Study: 17493108
Drug: Nicotine lozenges
Normalized name: nicotine Oral Lozenge
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotine lozenges
Study: 12786834
Drug: Topical 2%
Normalized name: menthol topical 2% topical gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 2% fusidic acid plus 0.1% betamethasone cream
Study: 12786834
Drug: Topical 2%
Normalized name: menthol topical 2% topical gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 2% mupirocin and 0.1% betamethasone cream
Study: 11198658
Drug: Mefloquine 25
Normalized name: mefloquine 250 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mefloquine 25 mg base/kg plus artesunate 4 mg/kg per day for 3 days (MAS3)
Study: 11198658
Drug: Quinine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quinine (10 mg salt/kg every 8 h) for 7 days (Q7)
Study: 9384466
Drug: Ro 48-8684
Normalized name: RO-5045337
DrugBank: RO-5045337 (DB14793)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ro 48-8684 (0.1-0.3-1 mg and 1-3-10 mg doses)
Study: 9384466
Drug: Midazolam (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam (0.1 mg(‐1) kg)
Study: 9384466
Drug: Ro 48-8684
Normalized name: RO-5045337
DrugBank: RO-5045337 (DB14793)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ro 48-8684 (10 mg)
Study: 9384466
Drug: Ro 48-8684
Normalized name: RO-5045337
DrugBank: RO-5045337 (DB14793)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ro 48-8684 (doses increasing from 1 to 10 mg)
Study: 25982391
Drug: Hop tablets
Normalized name: HOPS
DrugBank: Hops (DB10687)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hop tablets for 12 weeks
Study: 25982391
Drug: Placebo tablets
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets for 12 weeks
Study: 24456059
Drug: Environmental enrichment
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Environmental enrichment (EE) for 2 hours daily starting 24 hours post-injury
Study: 24456059
Drug: Simvastatin (Sim)
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Simvastatin (Sim) for 2 hours daily starting 24 hours post-injury
Study: 16042674
Drug: Candesartan (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Candesartan (4 mg day(‐1))
Study: 16042674
Drug: Valsartan (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valsartan (40 mg day(‐1))
Study: 8175622
Drug: half-dose T+K
Normalized name: Effer-K
Approvals — FDA: no, EMA: no, PMDA: no
Description: half-dose T+K (T/2 + K group)
Study: 2953870
Drug: Zoladex (sustained-release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zoladex (sustained-release luteinizing hormone-releasing hormone analogue) administered by subcutaneous injection every 28 days